United Therapeutics Earnings Call Signals Growth Ahead
United Therapeutics Corp. ((UTHR)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
United Therapeutics struck an upbeat tone on its latest earnings call, leaning on record revenue, robust Tyvaso growth and a packed pipeline to argue its pulmonary and transplant franchises are still in expansion mode. Executives acknowledged near‑term lumpiness from patient starts, distributor ordering and new competition, but framed these as timing issues rather than structural threats.
Record Revenue Clears $3 Billion Milestone
Full‑year 2025 revenue surpassed $3.0 billion for the first time in the company’s history, representing 11% growth over 2024 and underscoring durable demand in its core therapies. Management framed this new base as a launchpad for the next leg of growth, reinforcing confidence in the business even before factoring in new product launches.
Solid Fourth Quarter Caps the Year
Fourth‑quarter revenue reached $790 million, up 7% year on year, a slower pace than the full‑year but still positive amid seasonal and weather headwinds. Executives emphasized that Q4 and Q1 are typically lighter quarters for specialty drugs, suggesting the underlying trend remains stronger than the headline number.
Tyvaso and DPI Continue to Power Growth
Tyvaso delivered $464 million in Q4 sales, climbing 12% year over year and reaffirming its status as the company’s workhorse franchise. Within that, Tyvaso DPI posted striking 24% growth, highlighting continued physician and patient uptake of the dry‑powder format despite cough being a key side effect.
High‑Impact Pipeline Readouts on the Horizon
Investors face several near‑term binary catalysts, starting with an outcome study unblinding for a once‑daily “super prostacyclin” next week. The second pivotal trial in the TETON IPF program will unblind next month, and if it confirms prior data, United Therapeutics expects to file and launch an IPF indication by June 2027.
Tresmi Soft‑Mist Inhaler Targets Cough Burden
The company unveiled “Tresmi,” a proprietary treprostinil soft‑mist inhaler designed to sharply reduce the cough often seen with dry‑powder inhalers. Human studies so far suggest cough reductions approaching 90%, and management plans to file for approval this year with a commercial launch targeted for next year.
Transplant and Regenerative Platforms Advance
In transplantation, the Xeno porcine organ program now has two patients transplanted and doing well in an ongoing trial, with a six‑patient cohort targeted by summer and registration work eyed for 2027. Miromatrix has fully enrolled its first manufactured liver trial and expects regulatory feedback this year on liver and implanted kidney pathways.
Product Tweaks and New Data Support the Franchise
United Therapeutics is rolling out new 80‑mcg cartridges and 96/112‑mcg combination kits to give clinicians more dosing flexibility and convenience, which could help adherence and up‑titration. Early ARTISAN study data suggest that initiating patients on higher‑dose treprostinil may lower mean pulmonary arterial pressure and improve right ventricular function.
Long‑Term Growth Target Reaffirmed
Management reiterated its ambition to reach a $4.0 billion revenue run‑rate by the back half of 2027, or roughly $1.0 billion per quarter. Importantly for investors, they stressed this goal is achievable without contributions from the new pipeline launches, which would sit on top of that base.
Short‑Term Softness in Patient Starts
The company noted that new patient starts lagged referral trends, pointing to Q4 seasonality and severe winter weather in January as key drivers. Recent weeks in February have shown improvement, and executives expect trends in starts to realign more closely with robust referrals as conditions normalize.
Distributor Ordering Patterns Add Noise
United Therapeutics reminded investors that specialty distributor ordering is inherently seasonal, with lighter volumes typically seen in the first and fourth quarters. This variability can make near‑term revenue appear choppy, even when underlying demand from patients and prescribers is steady or improving.
Monitoring New Competitive Dynamics
Liquidia’s Yutrepia has created fresh competitive pressure, generating initial curiosity among physicians and patients in the inhaled treprostinil market. Management reported that referrals and prescriber metrics over recent months are at or above pre‑launch levels, but they are closely watching adoption patterns as the competitive landscape evolves.
Execution Risk Around Binary Catalysts
Several key value drivers depend on favorable trial readouts and regulatory approvals, including the super prostacyclin, TETON confirmation and Tresmi and IPF filings. Management highlighted that these are inherently binary events, offering significant upside if successful but also introducing execution and regulatory risk if timelines slip or data disappoint.
Long Dated but Ambitious Transplant Timelines
While early clinical progress in xenotransplantation and manufactured organs is encouraging, commercial impact is years away, with Xeno’s revenue potential framed around 2030. Multiple stealth and regenerative projects add to the long‑term story, but investors will need patience as these programs work through complex development and approval pathways.
Guidance Points to Renewed Growth Momentum
Looking ahead, management reiterated expectations for durable double‑digit revenue growth, with 2025 already above $3.0 billion and sequential growth expected to resume by the second quarter. They are targeting a $4.0 billion revenue run‑rate by late 2027, supported by three planned commercial launches tied to that year and strong referral trends through mid‑February.
United Therapeutics’ latest earnings call painted a picture of a company balancing near‑term volatility with powerful long‑term growth levers in pulmonary and transplant medicine. For investors, the story now hinges on upcoming trial unblindings and launches that could unlock new markets, while the core Tyvaso franchise continues to underpin a steadily rising revenue base.
